Advertisement

An Insight into Poliovirus Biology

  • R. Crainic
  • T. Couderc
  • A. Martin
  • C. Wychowski
  • M. Girard
  • F. Horaud
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 257)

Abstract

One of the most successful events in the control of infectious diseases has been the development of inactivated and oral poliovaccines in the 1950’s. The intensive use of vaccines in some areas of the world, like North America and Europe, has resulted in the disappearance of outbreaks of disease while, in many developing countries, poliomyelitis is still a major public health problem. However, this considerable accomplishment was achieved at a time when we had very little basic knowledge of poliovirus biology. This situation has changed dramatically within the last years, because, thanks to progress in molecular biology and immunochemistry, powerful new tools have become available. This has also created a favourable climate for improving the safety and the efficacy of currently used poliovaccines and for replacing them with a new one which is scientifically better designed. Nonetheless, in the near future the most predictable consequence of contemporary research on poliovirus will be the scientific explanation for poliovaccine efficacy which is still an enigmatic problem. This is the reason why poliovirus antigenicity and virulence has became an important field of investigation in the recent years. Beyond the problem of poliovaccine efficacy, the present studies on poliovirus also have an important cognitive aspect. The simplicity of the structure of poliovirion should allow elucidation of relationships between chemical structure of the genotype and biological functions of the phenotype.

Keywords

Antigenic Site Oral Poliovaccines Neutralization Epitope Live Vaccine Strain Poliovirus Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Almond, J.W., 1987, The attenuation of poliovirus neurovirulence, Ann. Rev. Microbiol., 41:153.CrossRefGoogle Scholar
  2. Blondel, B., Crainic, R., and Horodniceanu, F., 1982, Le polypeptide structural VP1 du poliovirus induit des anticorps neutralisants, C. r. hebd. Séanc. Acad. Sci., Paris, 294:91.Google Scholar
  3. Blondel, B., Akacem, O., Crainic, R., Couillin, P., and Horodniceanu,F., 1983, Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virion, Virology, 126:707.PubMedCrossRefGoogle Scholar
  4. Blondel, B., Crainic, C. , Fichot, O., Dufraisse, G., Candrea, A., Diamond, D., Girard, M., and Horaud, F., 1986, Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site, J. of Virol., 57:81.Google Scholar
  5. Emini, A., Kao, S.Y., Lewis, A.J., Wimmer, E., and Crainic, R., 1983, The functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies, J. Virol., 46:466.PubMedGoogle Scholar
  6. Fricks, C.E., Icenogle, J.P., and Hogle, J.M., 1985, Trypsin sensitivity of the Sabin strain of type 1 poliovirus : cleavage sites in virions and related particles, J. Virol. 54:856.PubMedGoogle Scholar
  7. Hogle, M.J., Chow, M., and Filman, J.D., 1985, Three-dimensional structure of poliovirus at 2.9 A resolution, Science, 229:1.CrossRefGoogle Scholar
  8. Horaud, F., Crainic, R., Van der Werf, S., Blondel, B., Wychowski, C, Akacem, U., Bruneau, P., Couillin, P., Siffert, U., and Girard, M., 1987, Identification and characterization of a continuous neutralization epitope (C3) present on type 1 poliovirus, Prog. Med. Virol., 34:129.PubMedGoogle Scholar
  9. Kohara, M., Abe, S., Komatsu, T., Tago, K., Arita, M, and Nomoto, A., 1988, A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain, J. Virol., 62:2828.PubMedGoogle Scholar
  10. Kuhn, R.J., Tada, H. , Ypma-Wong, M.F., Dunn, J.J., Semler, B., and Wimmer, E. , 1987, Construction of a “mutagenesis cartridge”, for poliovirus genome-linked viral protein : Isolation and characterization of viable and nonviable mutants. Proc. Natl. Acad. Sci. (USA), 85:519.CrossRefGoogle Scholar
  11. La Monica, N., Kupsky, W.J., and Racaniello, V.R., 1987a, Reduced mouse neurovirulence of poliovirus Type 2 Lansing antigenic variant selected with monoclonal antibodies, Virology. 161:429.PubMedCrossRefGoogle Scholar
  12. La Monica, N., Almond, J.W., and Racaniello, V.R., 1987b, A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans, J. Virol. , 61:2917.PubMedGoogle Scholar
  13. Martin, A., Wychowski, C, Couderc, T., Crainic, R., Hogle, J., and Girard, M., 1988, Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice, Embo J., 7:2839.PubMedGoogle Scholar
  14. Minor, P.D., Ferguson, M., Evans, D.M.A., Almond, J.W., and Icenogle, J.P., 1986, Antigenic structure of polioviruses of serotypes 1, 2 and 3, J. Gen. Virol. , 67:1283.PubMedCrossRefGoogle Scholar
  15. Murray, M.G., Kuhn, R.J., Avita, M., Kawamura, N., Nomoto, A., and Wimmer, E., 1988a, Poliovirus type I/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys, Proc. Natl. Acad. Sci. (USA). 85:3203.CrossRefGoogle Scholar
  16. Murray, M.G., Bradley, J., Yang, X.F., Wimmer, E., Moss, E.G., and Racaniello, V.R., 1988b, Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site 1, Science. 241:213.PubMedCrossRefGoogle Scholar
  17. Racaniello, V.R., 1987, Viral sequences required for neurovirulence of poliovirus, Bioassays, 5:266.CrossRefGoogle Scholar
  18. Rossman, M.G., Arnold, E., Erickson, J.W., Frankenberger, E.A., Griffith, J.P., Hecht, H.J., Johnson, J.E., Kamer, G., Luo, M., Mosser, A.G., Rueckert, R.R., Sherry, B., and Vriend, G., 1985, The structure of human common cold virus (rhinovirus 14) and its functional relationships to other picornaviruses, Nature, Lond., 317:145.CrossRefGoogle Scholar
  19. Stanway, G., Hughes, P.J., Westrop, G.D., Evans, D., Dum, G., Minor, P.D., Schild, G.C., and Almond, J.W., 1986, Construction of poliovirus intertypic recombinants by use of cDNA, J. Virol, 57:1187.PubMedGoogle Scholar
  20. Svehag, S.E., and Mandel, B., 1964, The formation and properties of poliovirus neutralizing antibody. I. 19s and 7s antibody formation. Differences in kinetics and antigen dose requirement for induction, J. Exp. Med., 119:1.PubMedCrossRefGoogle Scholar
  21. Van der Werf, S., Wychowski, C, Bruneau, P., Blondel, B., Crainic, R., Horodniceanu, F., and Girard, M., 1983, Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1, Proc. Natl. Acad. Sci. (USA), 80:5080.CrossRefGoogle Scholar
  22. Wychowski, C, Van der Werf, S., Siffert, O., Crainic, R., Bruneau, P., and Girard, M., 1983, A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1, Embo J., 2:2019.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • R. Crainic
    • 1
  • T. Couderc
    • 1
  • A. Martin
    • 2
  • C. Wychowski
    • 2
  • M. Girard
    • 2
  • F. Horaud
    • 1
  1. 1.Institut PasteurUnité de Virologie MédicaleParis 15France
  2. 2.Institut PasteurUnité de Virologie MoléculaireParis 15France

Personalised recommendations